Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Pazopanib in Renal Cell Carcinoma (VEG105192 Extension)
2006-002381-18Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC), sponsored by GSK. Primary endpoint: Safety and tolerability of pazopanib 800 mg daily. Started Jul 2006; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2006-002381-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002381-18.